The remains belonged to Robert Martin, the diver who vanished in 2006 after a trip about 20 miles offshore from Ponce Inlet. Fulcher, also an experienced diver, said the final piece of the puzzle was ...

While the trend has sparked solitary, some caution that at the 'end of the day, a white ginger is white, which carries with it all the privileges, perspectives, and experiences common with being ...

From tailored jackets and silk ties to playful fedoras and pocket squares, Black dandyism isn’t just a campy style—it has served as a powerful political act throughout history. Black dandyism ...

Novartis AG has agreed to buy U.S. biotech firm Regulus Therapeutics Inc. in a deal that could be valued at up to $1.7 billion. The Swiss company will pay $7 a share in cash up-front through a ...

Novartis plans to acquire clinical stage biotech Regulus Therapeutics in a deal worth up to $1.7 billion. Under the terms announced April 30, the Swiss drugmaker will make an upfront payment of $ ...

Shares of Regulus Therapeutics more than doubled after the company agreed to be acquired by Novartis in a deal with an equity value of up to $1.7 billion. The stock was changing hands at $7.78 in ...

Novartis NOVN0.23%increase; green up pointing triangle has agreed to acquire Regulus Therapeutics RGLS 0.38%increase; green up pointing triangle for a total equity value of up to roughly $1.7 billion.

Novartis (NYSE:NVS) has agreed to acquire biopharmaceutical firm Regulus Therapeutics (NASDAQ:RGLS) for an initial payment of $7.00 a share in cash at closing, or $0.8B. The upfront cash portion ...

Novartis to acquire Regulus for $7/share upfront, a 108% premium to April 29 close and 274% over 60-day VWAP. The total deal could reach $1.7 billion if farabursen gains regulatory approval ...

Novartis has agreed to acquire Regulus Therapeutics for a total equity value of up to roughly $1.7 billion. With the merger, the Swiss pharmaceutical company aims to bring to more patients ...

April 30 (Reuters) - Novartis (NOVN.S), opens new tab has agreed to buy Regulus Therapeutics (RGLS.O), opens new tab for up to $1.7 billion, giving the Swiss drugmaker access to an experimental ...